Search conditions, treatments, research reviews and articles. Press Enter to see all results, Esc to close.
Search conditions, treatments, research reviews and articles. Press Enter to see all results, Esc to close.
Blog
October 29, 2026
Autologous serum eye drops are prescribed drops made from a patient's own blood serum and prepared for ocular use by an appropriately equipped provider. They contain biologic components that may support a damaged ocular surface and are considered for selected patients with severe dry eye, persistent epithelial problems, or other difficult surface conditions. They require professional preparation, careful storage, and follow-up; they are not a home-made substitute for ordinary lubricants. [1]
The treatment is often discussed after several conventional approaches have provided inadequate relief. That can make it sound like a universal next step for any uncomfortable eye. In practice, the diagnosis, condition of the cornea, previous treatment, and the patient's ability to maintain the storage routine all matter.
The most useful decision is not simply whether serum tears are “natural.” It is whether this particular blood-derived preparation addresses the problem identified in your eyes, whether the expected benefit justifies its burden and cost, and how it will fit with the rest of the treatment plan.
In this article
Serum is the liquid obtained after blood has clotted and the clot and cells have been separated. It contains proteins and other biologically active components. Researchers have studied serum tears partly because some of these components overlap with substances relevant to epithelial maintenance and repair. [1,2]
Artificial tears primarily provide lubrication and modify the tear-film environment through their formulation. Serum tears add a different biologic mixture. This distinction provides a rationale for use in selected damaged surfaces, but it does not mean that every serum preparation is identical or that more biologic material is always better.
The serum is not a stem-cell treatment, a gene therapy, or a blood transfusion into the eye. It is also not identical to the tears the lacrimal system normally produces. Preparation, dilution, the patient's blood composition, and storage can influence the final product.
Autologous means the blood comes from the person who will use the drops. Allogeneic products use another donor source and involve different considerations. Platelet-rich plasma and related preparations are also distinct products, with different processing and biologic composition. Results from one should not automatically be transferred to another. [3]
Serum tears are commonly discussed in refractory aqueous-deficient dry eye and selected epithelial-healing problems. Other potential applications include some neurotrophic, cicatrizing, or neuropathic surface conditions, under specialist supervision. The evidence and practical requirements vary across these groups. [1,2]
The decision should follow an assessment of what is still untreated. Someone with significant eyelid exposure needs an exposure plan. Someone with active infection needs infection treatment. A person with severe inflammatory disease may still require anti-inflammatory or systemic management even if serum tears are added.
Netra's dry-eye treatment guide places biologic tears among several advanced options. It is useful to understand this broader pathway before assuming that failure of one lubricant means all standard treatment has been exhausted.
When the ocular surface remains compromised despite an appropriate regimen, serum tears may be considered as an additional treatment. The clinician should define the target: symptoms, epithelial staining, recurrent breakdown, or another measurable problem. Continuing every previous drop without reviewing its purpose may create an unnecessarily complicated routine.
Associated autoimmune disease may require coordinated care. Serum tears do not replace investigation of systemic symptoms or treatment of the underlying autoimmune disorder. Netra's guide to dry eye and autoimmune disease explains why the eye and systemic plans may need to proceed together.
An epithelial defect is an area where the cornea's protective surface has not closed. Reduced sensation, exposure, inflammation, toxicity, and systemic factors can contribute. A specialist must establish why the defect persists and whether infection is present before selecting treatment.
Serum tears may be part of that plan, but a prescription does not remove the need for close monitoring or other measures. A defect that looks small can still be clinically important. Little pain is not reassuring when corneal sensation is reduced. [1]
Some patients experience severe pain associated with abnormal corneal nerve function, sometimes with relatively limited routine surface findings. Serum tears have been studied in this setting, but the evidence is less definitive than a guaranteed nerve-restoration claim would suggest.
A retrospective study of 16 patients reported reduced pain and changes in nerve measurements after serum-tear treatment. Because it was not a randomized, masked treatment trial, the findings support further investigation and selected clinical use rather than establishing predictable benefit for every patient. Neuropathic pain may require a broader management plan. [4]
The evidence supports considering serum tears in selected difficult cases, while leaving important uncertainty about the best preparation, concentration, and duration. Reviews can reach different conclusions because they include different trials, comparators, and patient populations.
A 2023 systematic review using Cochrane methods included six randomized trials with 116 participants. It found low- or very-low-certainty evidence for some outcomes and uncertainty for several ocular-surface measures. This is a reason to avoid overselling the treatment, not proof that no patient can benefit. [5]
A 2024 meta-analysis included 12 randomized trials and reported advantages over artificial tears in several symptom and clinical measures. A separate 2025 review again emphasized small samples and variable designs. Taken together, the literature suggests a potentially useful option whose effect needs to be evaluated in the actual patient rather than assumed from a pooled average. [6,7]
When reading a study, distinguish a change in a symptom questionnaire from closure of an epithelial defect or improved visual function. These are all relevant, but they answer different questions. An improvement in tear breakup time does not demonstrate permanent restoration of the lacrimal glands.
Published studies have used concentrations including 20%, 50%, and undiluted serum. A concentration describes the formulation; it is not a simple ranking of treatment strength. The preparation method and diagnosis also matter, and higher concentration is not automatically the best choice.
A small randomized study comparing 20% and 50% preparations in refractory dry eye reported different responses according to disease severity. Its findings can inform clinical judgment, but they do not establish a universal rule for every cause of ocular-surface disease. [8]
A later concentration-focused systematic review found substantial variation across studies and did not identify a clear symptom advantage that made one concentration universally superior. This reinforces the need to interpret the prescription in context. Do not change the concentration, dilute a bottle, or combine batches yourself. [9]
If your clinician changes the formulation, ask what prompted the change and what outcome will be checked. A clear reason is more informative than the assumption that a higher percentage must produce faster healing.
The process generally involves a prescription, blood collection, serum separation, preparation under appropriate controlled conditions, dispensing into suitable containers, and a cold-storage plan. The provider should supply patient-specific instructions for transport, use, and disposal. This overview explains the pathway; it is not a recipe for home preparation. [1,2]
Before collection, disclose relevant medical conditions, medicines, and difficulties with blood draws. The prescribing and collection teams determine whether the person can safely provide the required sample and whether any screening or other precautions are necessary. The amount collected and the logistics vary by provider and treatment plan.
The laboratory's work matters because serum can support microbial growth if contaminated. A product being made from your own blood does not eliminate contamination during collection, preparation, transport, or use. The final drops still need the handling standards required for a vulnerable ocular surface.
Ask who prepares the product, how it is labeled, and whom to contact if a bottle or shipment is damaged. You should be able to identify the prescription, batch, storage instructions, and discard rules without relying on memory.
Many programs supply frozen containers and require an in-use container to remain refrigerated. However, exact temperatures, thawing instructions, expiry dates, and permitted use after opening depend on the validated product and container. Follow the dispensing provider's instructions rather than a generic online schedule. [1,10]
Different published protocols illustrate why there is no universal bottle rule. A manufacturing-validation study for a particular nondiluted serum product established a defined frozen shelf life and a 24-hour use period after opening its single-use applicator. That does not mean a different multidose product should be used or discarded on the same timetable. [10]
Do not refreeze a thawed container or leave it at room temperature unless the provider specifically permits that handling. If refrigeration fails, a shipment arrives unexpectedly warm, or travel plans interrupt storage, ask the provider whether the product remains usable. The appearance of the liquid cannot reliably establish its microbiologic safety.
Decide where the supply will be stored, how the in-use bottle will be labeled, and how doses will be managed at work. Check whether the treatment plan requires a cooler or another validated transport method. Do not assume that a household insulated bag maintains a safe temperature indefinitely.
Keep the written storage instructions with the supplies. If a family member assists, make sure they understand the difference between unopened frozen stock and the current in-use container. An organized routine helps prevent both contamination risk and avoidable waste.
For travel, plan ahead with the dispensing team and check the relevant carrier rules for liquids and cooling materials. A trip should not force you to improvise a storage method after leaving home.
The prescriber determines frequency and how serum tears fit with lubricants, anti-inflammatory drops, ointments, or other medicines. Do not assume that adding serum means every other treatment should stop. Conversely, ask whether an older product is still needed so that the regimen remains purposeful.
Wash and dry your hands, avoid touching the bottle tip to the eye or other surfaces, and follow the product's instructions. If the tip is contaminated, the container is damaged, or the liquid changes unexpectedly, contact the provider for advice. Do not share serum drops with another person. [11]
If several drops are used, obtain a written schedule and ask about spacing. The aim is reliable administration, not simply the largest possible number of treatments. Tell the clinician if the burden is causing missed doses.
These treatments can appear in the same patient's care plan, but they are not automatically used at the same time or in the same way. The lens fitter and prescriber should specify whether serum is used before or after lens wear and whether any nonstandard reservoir use is intended.
Do not add serum tears to the scleral-lens bowl without explicit instructions. Filling fluid remains against the cornea, and a prescribed drop's usual schedule cannot simply be translated into hours of reservoir exposure. The standard filling and cleaning instructions remain important; Netra’s guide to scleral lenses explains them in more detail. [12]
Potential problems include contamination, irritation, an unsuitable formulation, and progression of the underlying condition despite treatment. Small studies do not fully define uncommon harms. An absence of reported complications in a particular trial is not the same as proof that the product is risk-free. [2,5]
New pain, discharge, substantial redness, light sensitivity, or reduced vision requires prompt contact with the eye-care clinician. Seek urgent care when symptoms are significant or worsening. A person being treated for a persistent defect should not assume that a new symptom is an expected phase of healing.
If contamination is suspected, do not continue using that container while waiting for an ordinary follow-up. Ask the prescriber or dispensing provider how to handle the product and maintain necessary treatment. Keep the label and batch information available.
The phrase “made from your own blood” can feel reassuring, but it should not replace practical scrutiny. Patient selection, quality of preparation, the cold chain, and the actual use routine all contribute to safety.
There is no single US price. The concentration, prescription volume, collection arrangements, supply duration, delivery, and provider affect the quotation. A longer supply can have a lower monthly equivalent but a larger up-front expense and more demanding storage requirements.
As a concrete example, the San Diego Eye Bank's patient information page listed the following all-inclusive prices when checked on October 29, 2026. The page describes inclusion of blood draw, processing, preparation, and delivery. These are that provider's published examples, not a Netra fee schedule or a guarantee of availability for a New Jersey patient. [13]
| Published supply option | Listed price | Simple monthly equivalent |
|---|---|---|
| One month | $225 | $225 |
| Three months | $390 | $130 |
| Six months | $600 | $100 |
The monthly equivalents are arithmetic comparisons, not a prediction of how long a prescribed quantity will last. Confirm the concentration, dosing assumptions, included services, shipping location, and current quote before ordering.
Vital Tears, a separate national provider, states that pricing depends on the physician's treatment plan and that its service is generally self-pay, although some patients may obtain reimbursement. Its patient page asks people to contact its patient services team for cost information rather than listing a universal price. [14]
Ask whether the quote includes blood collection, required testing, preparation, shipping, containers, and repeat collection. Clarify what happens if treatment is stopped early, the product is damaged, or the prescription changes. Compare the total treatment cost rather than a bottle price that excludes essential services.
Ask the insurer and supplier about documentation before assuming coverage. A pharmacy receipt, diagnosis, or prescription does not automatically guarantee reimbursement. Cost should be discussed alongside the measurable treatment goal and the planned reassessment date.
Serum tears target the ocular surface through a prescribed biologic preparation. NRT is a separate adjunctive program. The relevant question is whether an individualized integrative plan can help with remaining symptoms, daily exposures, or systemic contributors while the prescribed surface treatment continues.
Netra's dry-eye treatment approach describes adjunctive attention to surface comfort and broader contributors. For a patient using serum tears, the starting point should be the reason they were prescribed: severe aqueous deficiency, an epithelial-healing problem, neuropathic symptoms, or another defined diagnosis. These situations require different goals and restrictions. [15]
For stable chronic dry eye, a goal might be better reading tolerance or a more manageable daily symptom burden. For a persistent epithelial defect, the immediate goal is reliable specialist-directed healing and protection; an elective traditional ocular procedure is not appropriate simply because the patient wants additional support.
If pain has a neuropathic component, the plan should distinguish symptom relief from objective nerve measurements. Neither a promising serum-tear study nor a theoretical neurotrophic mechanism establishes that the complete NRT program restores corneal nerves or will eliminate pain in a particular individual.
The care team can record symptoms, functional tasks, tear or staining findings, and changes in medication. Improvement is easier to interpret when serum-tear initiation, dose changes, and adjunctive treatment dates are documented separately.
Trials of acupuncture in dry-eye populations have examined symptoms and tear-related outcomes, with results varying across protocols and comparison groups. They do not establish the effectiveness of adding NRT to serum tears, and they should not be used to promise that a patient can discontinue the prescribed drops. [16]
If an adjunctive trial is appropriate, agree on what would constitute meaningful benefit and when it will be reassessed. A vague goal of “improving healing” is less useful than a specific symptom or functional target accompanied by continued corneal examination.
No herb, oil, ghee, supplement extract, or other ingredient should be mixed into serum tears. Do not dilute them or transfer them into an unapproved container. A professionally prepared product has specific handling requirements; adding a supposedly beneficial ingredient can change its properties and introduce contamination. [11]
Traditional ocular procedures require separate screening. Netra's physician collaboration guidance excludes active infection and unhealed epithelial defects from such procedures and calls for caution around recent surgery. Serum-tear use may indicate precisely the kind of fragile surface that makes this assessment especially important. [17]
Sleep disruption, screen demands, medication effects, nutrition, and systemic disease can influence a person's overall symptom burden or ability to follow care. They deserve a targeted review. They should not be used to dismiss genuine epithelial disease or to imply that stress is the explanation for an abnormal corneal examination.
Any oral botanical plan needs a medication and health review. Laboratory findings about antioxidant or inflammatory pathways are not equivalent to evidence that a particular formula improves serum-tear outcomes. The purpose of an integrative consultation is to develop a coherent, measurable plan, not to add products indiscriminately.
Before starting, ask what should improve and how it will be measured. In chronic dry eye, this may include symptoms, staining, and everyday function. In an epithelial defect, the surface measurements and safety findings are particularly important, and follow-up may be much more frequent.
Do not judge the treatment solely by the first dose or by another patient's experience. Equally, do not continue an expensive therapy indefinitely without reassessment. If improvement is limited, the clinician can review diagnosis, adherence, formulation, storage, and remaining contributors.
Bring the dispensing instructions and all current drops to a Netra consultation if you want to discuss adjunctive care. Prescribing, preparing, or supplying serum tears should remain with the appropriately authorized eye-care and production providers; an NRT discussion does not imply that Netra manufactures or sells the product.
They may be helpful in selected severe or refractory conditions, but they are not automatically better for every patient. Trials and reviews differ in their findings and certainty. The decision should reflect the diagnosis, measurable goal, preparation burden, and response to a sensible conventional plan. [5,6]
They are made from serum after blood has clotted and the clot and cells have been separated. The final preparation is formulated for ocular use. It is not whole blood, a stem-cell injection, or a gene therapy, and it should never be prepared at home. [1]
No universal rule establishes that. Concentration, preparation, diagnosis, and the outcome being measured all matter. Some studies suggest differences in particular populations, but the evidence does not justify changing the formulation without the prescriber's direction. [8,9]
Response depends on the condition and the outcome. Comfort and epithelial findings may change on different schedules. Ask for an individualized review point, and report worsening symptoms earlier. A generic promise of improvement within a fixed number of days is not reliable.
Follow the instructions for your specific product and container. Published protocols use different discard periods, and one provider's rule cannot safely be applied to another preparation. If the label is unclear, contact the dispensing team before use. [1,10]
Often a travel plan can be arranged, but the required storage conditions must be maintained. Ask the provider about validated cooling, transport duration, and what to do if temperatures are uncertain. Do not assume a product remains safe because it still looks clear.
Coverage varies, and some providers describe the treatment as generally self-pay. Request an itemized quotation and ask what documentation is available for a claim. Confirm the insurer's requirements before relying on reimbursement. [14]
That should not be assumed or promised. NRT may be considered for a defined adjunctive goal while the prescribing clinician monitors the surface. Any reduction or discontinuation of serum tears should follow clinical reassessment and the prescriber's instructions.
A new painful red eye, especially with blurred vision or light sensitivity, needs prompt assessment. Serum tears are not a general treatment for infection and should not delay diagnosis. Follow the clinician's instructions about the current prescription while the new problem is evaluated.
Ask which finding the treatment is intended to improve and how you will know whether it has helped. Pair that answer with clear instructions for storage, use, follow-up, and total cost. This turns an appealing treatment concept into a practical, assessable care plan.
Sources checked October 29, 2026. Netra pages describe the provider’s approach; they do not independently establish treatment efficacy.
This article provides general education and does not replace an individual eye examination, diagnosis or treatment plan. Seek prompt clinical advice for new pain, a red eye with reduced vision or a significant visual change.
